More recently, evidence-based medicine has provided clinicians with the opportunity to make treatment decisions based on high-quality clinical evidence.
NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...